Companies are spending big bucks advertising weight-loss drugs like Rybelsus, seeing huge potential in capitalizing on the popularity of Ozempic. But in Canada, so-called "reminder ads" can give only the name of the medication, not what it's for, telling people to ask their doctor for details. Ad man Terry O’Reilly says it can result in bad ads that turn people off, and pharmaceutical policy expert Barbara Mintzes says reminder ads can lead to overtreatment and high costs, doing more harm than good.
